Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Published:2020-02-12 Issue:3 Volume:189 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

LaCasce Ann S.¹^ORCID,Bociek R. Gregory²,Sawas Ahmed³,Caimi Paolo⁴,Agura Edward⁵,Matous Jeffrey⁶,Ansell Stephen M.⁷,Crosswell Howland E.⁸,Islas‐Ohlmayer Miguel⁹,Behler Caroline¹⁰,Cheung Eric¹¹,Forero‐Torres Andres¹²,Vose Julie²,O’Connor Owen A.³,Josephson Neil¹³,Wang Yinghui¹³,Advani Ranjana¹⁴

Affiliation:

1. Dana‐Farber Cancer Institute Boston MA USA

2. University of Nebraska Medical Center Omaha NE USA

3. Columbia University Medical Center New York NY USA

4. University Hospitals Seidman Cancer Center Cleveland OH USA

5. Charles A. Sammons Cancer Center Dallas TX USA

6. Colorado Blood Cancer Institute Denver CO USA

7. Mayo Clinic Rochester MN USA

8. St. Francis Hospital Greenville SC USA

9. The Jewish Hospital‐Mercy Health Cincinnati OH USA

10. Pacific Hematology Oncology Associates San Francisco CA USA

11. The Oncology Institute of Hope & Innovation Whittier CA USA

12. University of Alabama at Birmingham Birmingham AL USA

13. Seattle Genetics, Inc Bothell WA USA

14. Stanford Cancer Institute Stanford CA USA

Funder

Seattle Genetics

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16499

Reference9 articles.

1. Revised Response Criteria for Malignant Lymphoma

2. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

3. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy

4. Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

5. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

2. Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse;Leukemia & Lymphoma;2024-09-03

3. Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era;Seminars in Hematology;2024-06

5. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease;American Society of Clinical Oncology Educational Book;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3